These results suggest targeting Cdc42 with the small molecule inhibitor AZA197 in colon cancer cells can effectively modulate PAK/ERK signaling interfering with Cyclin D1 expression to affect colon cancer cell proliferation. This evidence concerns the gene CDC42 and malignant colon neoplasm.